Literature DB >> 32427277

Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.

Mike Z Zhai1, Carolyn T Lye2,3, Aaron S Kesselheim1.   

Abstract

Entities:  

Year:  2020        PMID： 32427277     DOI： 10.1001/jamainternmed.2020.2402

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  4 in total

1.  Using Twitter data to understand public perceptions of approved versus off-label use for COVID-19-related medications.

Authors:  Yining Hua; Hang Jiang; Shixu Lin; Jie Yang; Joseph M Plasek; David W Bates; Li Zhou
Journal:  J Am Med Inform Assoc       Date:  2022-09-12       Impact factor: 7.942

2.  Scientific Publications During the COVID-19 Pandemic.

Authors:  Ana Carolina Sepúlveda-Vildósola; Juan Manuel MejÍa-Aranguré; Carolina Barrera-Cruz; Natxieli Alexandra Fuentes-Morales; Carlos Rodriguez-Zeron
Journal:  Arch Med Res       Date:  2020-05-25       Impact factor: 2.235

3.  Mortality in children with cancer and SARS-CoV-2 in Latin America: A systematic review.

Authors:  Elisa Dorantes-Acosta; Diana Ávila-Montiel; Jesús Domínguez Rojas; Patricia Parra-Nigañez; Liliana Velasco-Hidalgo; Sergio Arias; Lourdes Gutiérrez-Rivera; Luis Juárez-Villegas; Horacio Márquez-González
Journal:  Front Pediatr       Date:  2022-08-09       Impact factor: 3.569

4.  Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients.

Authors:  Hsiang-Ling Ho; Fang-Yu Wang; Hao-Ru Lee; Ya-Lan Huang; Chien-Liang Lai; Wen-Chin Jen; Shie-Liang Hsieh; Teh-Ying Chou
Journal:  Lancet Reg Health West Pac       Date:  2020-10-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.